Exact Mass: 516.2458

Udenafil

C25H36N6O4S (516.2519)

Udenafil is a new phosphodiesterase type 5 (PDE5) inhibitor used to treat erectile dysfunction (ED). It has been approved in South Korea and will be marketed under the brand name Zydena. It is not yet approved for use in the U.S., E.U., or Canada. G - Genito urinary system and sex hormones > G04 - Urologicals > G04B - Urologicals > G04BE - Drugs used in erectile dysfunction D004791 - Enzyme Inhibitors > D010726 - Phosphodiesterase Inhibitors > D058986 - Phosphodiesterase 5 Inhibitors C471 - Enzyme Inhibitor > C744 - Phosphodiesterase Inhibitor > C2127 - cGMP Phosphodiesterase Inhibitor

Austalide A

C28H36O9 (516.2359)

Austalide A is a metabolite of Aspergillus ustu Metabolite of Aspergillus ustus.

PA(2:0/20:3(5Z,8Z,11Z)-O(14R,15S))

C25H41O9P (516.2488)

PA(2:0/20:3(5Z,8Z,11Z)-O(14R,15S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:3(5Z,8Z,11Z)-O(14R,15S)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 14,15-epoxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:3(5Z,8Z,11Z)-O(14R,15S)/2:0)

C25H41O9P (516.2488)

PA(20:3(5Z,8Z,11Z)-O(14R,15S)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(5Z,8Z,11Z)-O(14R,15S)/2:0), in particular, consists of one chain of one 14,15-epoxyeicosatrienoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(2:0/20:3(5Z,8Z,14Z)-O(11S,12R))

C25H41O9P (516.2488)

PA(2:0/20:3(5Z,8Z,14Z)-O(11S,12R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:3(5Z,8Z,14Z)-O(11S,12R)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 11,12-epoxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:3(5Z,8Z,14Z)-O(11S,12R)/2:0)

C25H41O9P (516.2488)

PA(20:3(5Z,8Z,14Z)-O(11S,12R)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(5Z,8Z,14Z)-O(11S,12R)/2:0), in particular, consists of one chain of one 11,12-epoxyeicosatrienoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(2:0/20:3(5Z,11Z,14Z)-O(8,9))

C25H41O9P (516.2488)

PA(2:0/20:3(5Z,11Z,14Z)-O(8,9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:3(5Z,11Z,14Z)-O(8,9)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 8,9--epoxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:3(5Z,11Z,14Z)-O(8,9)/2:0)

C25H41O9P (516.2488)

PA(20:3(5Z,11Z,14Z)-O(8,9)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(5Z,11Z,14Z)-O(8,9)/2:0), in particular, consists of one chain of one 8,9--epoxyeicosatrienoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(2:0/20:3(8Z,11Z,14Z)-O(5,6))

C25H41O9P (516.2488)

PA(2:0/20:3(8Z,11Z,14Z)-O(5,6)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:3(8Z,11Z,14Z)-O(5,6)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 5,6-epoxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:3(8Z,11Z,14Z)-O(5,6)/2:0)

C25H41O9P (516.2488)

PA(20:3(8Z,11Z,14Z)-O(5,6)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(8Z,11Z,14Z)-O(5,6)/2:0), in particular, consists of one chain of one 5,6-epoxyeicosatrienoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(2:0/20:4(5Z,8Z,11Z,14Z)-OH(20))

C25H41O9P (516.2488)

PA(2:0/20:4(5Z,8Z,11Z,14Z)-OH(20)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:4(5Z,8Z,11Z,14Z)-OH(20)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 20-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:4(5Z,8Z,11Z,14Z)-OH(20)/2:0)

C25H41O9P (516.2488)

PA(20:4(5Z,8Z,11Z,14Z)-OH(20)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(20)/2:0), in particular, consists of one chain of one 20-Hydroxyeicosatetraenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(2:0/20:4(6E,8Z,11Z,14Z)-OH(5S))

C25H41O9P (516.2488)

PA(2:0/20:4(6E,8Z,11Z,14Z)-OH(5S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:4(6E,8Z,11Z,14Z)-OH(5S)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 5-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:4(6E,8Z,11Z,14Z)-OH(5S)/2:0)

C25H41O9P (516.2488)

PA(20:4(6E,8Z,11Z,14Z)-OH(5S)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(6E,8Z,11Z,14Z)-OH(5S)/2:0), in particular, consists of one chain of one 5-Hydroxyeicosatetraenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(2:0/20:4(5Z,8Z,11Z,14Z)-OH(19S))

C25H41O9P (516.2488)

PA(2:0/20:4(5Z,8Z,11Z,14Z)-OH(19S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:4(5Z,8Z,11Z,14Z)-OH(19S)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 19-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:4(5Z,8Z,11Z,14Z)-OH(19S)/2:0)

C25H41O9P (516.2488)

PA(20:4(5Z,8Z,11Z,14Z)-OH(19S)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(19S)/2:0), in particular, consists of one chain of one 19-Hydroxyeicosatetraenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(2:0/20:4(5Z,8Z,11Z,14Z)-OH(18R))

C25H41O9P (516.2488)

PA(2:0/20:4(5Z,8Z,11Z,14Z)-OH(18R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:4(5Z,8Z,11Z,14Z)-OH(18R)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 18-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/2:0)

C25H41O9P (516.2488)

PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/2:0), in particular, consists of one chain of one 18-Hydroxyeicosatetraenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(2:0/20:4(5Z,8Z,11Z,14Z)-OH(17))

C25H41O9P (516.2488)

PA(2:0/20:4(5Z,8Z,11Z,14Z)-OH(17)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:4(5Z,8Z,11Z,14Z)-OH(17)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 17-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:4(5Z,8Z,11Z,14Z)-OH(17)/2:0)

C25H41O9P (516.2488)

PA(20:4(5Z,8Z,11Z,14Z)-OH(17)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(17)/2:0), in particular, consists of one chain of one 17-Hydroxyeicosatetraenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(2:0/20:4(5Z,8Z,11Z,14Z)-OH(16R))

C25H41O9P (516.2488)

PA(2:0/20:4(5Z,8Z,11Z,14Z)-OH(16R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:4(5Z,8Z,11Z,14Z)-OH(16R)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 16-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:4(5Z,8Z,11Z,14Z)-OH(16R)/2:0)

C25H41O9P (516.2488)

PA(20:4(5Z,8Z,11Z,14Z)-OH(16R)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(16R)/2:0), in particular, consists of one chain of one 16-Hydroxyeicosatetraenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(2:0/20:4(5Z,8Z,11Z,13E)-OH(15S))

C25H41O9P (516.2488)

PA(2:0/20:4(5Z,8Z,11Z,13E)-OH(15S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:4(5Z,8Z,11Z,13E)-OH(15S)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 15-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:4(5Z,8Z,11Z,13E)-OH(15S)/2:0)

C25H41O9P (516.2488)

PA(20:4(5Z,8Z,11Z,13E)-OH(15S)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,13E)-OH(15S)/2:0), in particular, consists of one chain of one 15-Hydroxyeicosatetraenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(2:0/20:4(5Z,8Z,10E,14Z)-OH(12S))

C25H41O9P (516.2488)

PA(2:0/20:4(5Z,8Z,10E,14Z)-OH(12S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:4(5Z,8Z,10E,14Z)-OH(12S)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 12-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:4(5Z,8Z,10E,14Z)-OH(12S)/2:0)

C25H41O9P (516.2488)

PA(20:4(5Z,8Z,10E,14Z)-OH(12S)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,10E,14Z)-OH(12S)/2:0), in particular, consists of one chain of one 12-Hydroxyeicosatetraenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(2:0/20:4(5E,8Z,12Z,14Z)-OH(11R))

C25H41O9P (516.2488)

PA(2:0/20:4(5E,8Z,12Z,14Z)-OH(11R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:4(5E,8Z,12Z,14Z)-OH(11R)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 11-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:4(5E,8Z,12Z,14Z)-OH(11R)/2:0)

C25H41O9P (516.2488)

PA(20:4(5E,8Z,12Z,14Z)-OH(11R)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5E,8Z,12Z,14Z)-OH(11R)/2:0), in particular, consists of one chain of one 11-Hydroxyeicosatetraenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(2:0/20:4(5Z,7E,11Z,14Z)-OH(9))

C25H41O9P (516.2488)

PA(2:0/20:4(5Z,7E,11Z,14Z)-OH(9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:4(5Z,7E,11Z,14Z)-OH(9)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 9-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:4(5Z,7E,11Z,14Z)-OH(9)/2:0)

C25H41O9P (516.2488)

PA(20:4(5Z,7E,11Z,14Z)-OH(9)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,7E,11Z,14Z)-OH(9)/2:0), in particular, consists of one chain of one 9-Hydroxyeicosatetraenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

Ejap 2

C28H36O9 (516.2359)

Vaalens 5

C28H36O9 (516.2359)

Arisanschinin J

C28H36O9 (516.2359)

deoxymorellin

C32H36O6 (516.2512)

Triptogelin D-1|triptogelin D1

C28H36O9 (516.2359)

Citreohybriddione A

C28H36O9 (516.2359)

(1alpha,2beta,8beta,9beta)-1,2,8-tris(acetyloxy)-9-(benzoyloxy)dihydro-beta-agarofuran|rel-octahydro-2,2,5a,9-tetramethyl-2H-3,9a-methano-1-benzoxepin-4,5,6,7-tetrol 4,6,7-triacetate 5-benzoate

C28H36O9 (516.2359)

9beta-amoorastatin

C28H36O9 (516.2359)

1,6,14-Triacetoxy-2,9-dibenzoyloxydihydro-alpha-agarofuran

C28H36O9 (516.2359)

1beta,6alpha,8alpha-triacetoxy-9beta-benzoyloxy-beta-dihydroagarofuran

C28H36O9 (516.2359)

schilancidilactone A

C28H36O9 (516.2359)

1alpha,6alpha,14-triacetoxy-9beta-benzoyloxydihydro-beta-agarofuran

C28H36O9 (516.2359)

1alpha-cinnamoyloxy-6beta,9beta-diacetoxy-2beta,4beta-dihydroxydihydro-beta-agarofuran|6,9-Di-Ac,1-cinnamoyl-1,2,4,6,9-Pentahydroxydihydro-beta-agarofuran

C28H36O9 (516.2359)

(22SR,23SR,24RS,25SR)-5alpha,6beta:12alpha,22:21,24-triepoxy-12beta,17beta,25-trihydroxy-1-oxo-with-2-en-26,23-olide|jaborosalactone 36

C28H36O9 (516.2359)

C28H36O9

C28H36O9 (516.2359)

wuweizidilactone N

C28H36O9 (516.2359)

1beta,8beta,13-Triacetoxy-9beta-benzoyloxy-beta-dihydroagarofuran

C28H36O9 (516.2359)

Kupitengester 4

C28H36O9 (516.2359)

1beta,2beta,6alpha-triacetoxy-9alpha-benzoyloxy-beta-dihydroagarofuran|1beta,2beta,6alpha-triacetoxy-9alpha-benzoyloxydihydro-beta-agarofuran|triptogelin C-1

C28H36O9 (516.2359)

Amoorastatone

C28H36O9 (516.2359)

forrestin F

C28H36O9 (516.2359)

schinarisanlactone A

C28H36O9 (516.2359)

Pro Asp Ala Lys Ser

C21H36N6O9 (516.2544)

Gln Asn Leu Glu

C21H36N6O9 (516.2544)

C28H36O9_(1R,2R,4S,16R,17R,20S)-13,20-Dimethoxy-4,7,17,22,22-pentamethyl-11-oxo-5,10,21,23-tetraoxahexacyclo[18.2.1.0~1,17~.0~4,16~.0~6,14~.0~8,12~]tricosa-6(14),7,12-trien-2-yl acetate

C28H36O9 (516.2359)

(1R,2R,4S,16R,17R,20S)-13,20-dimethoxy-4,7,17,22,22-pentamethyl-11-oxo-5,10,21,23-tetraoxahexacyclo[18.2.1.0¹,¹⁷.0⁴,¹⁶.0⁶,¹⁴.0⁸,¹²]tricosa-6(14),7,12-trien-2-yl acetate

C28H36O9 (516.2359)

(1R,2R,4S,16R,17R,20S)-13,20-dimethoxy-4,7,17,22,22-pentamethyl-11-oxo-5,10,21,23-tetraoxahexacyclo[18.2.1.0¹,¹?.0?,¹?.0?,¹?.0?,¹²]tricosa-6(14),7,12-trien-2-yl acetate

C28H36O9 (516.2359)

Glu Ile Gln Gln

C21H36N6O9 (516.2544)

Glu Leu Gln Gln

C21H36N6O9 (516.2544)

Glu Gln Ile Gln

C21H36N6O9 (516.2544)

Glu Gln Leu Gln

C21H36N6O9 (516.2544)

Glu Gln Gln Ile

C21H36N6O9 (516.2544)

Glu Gln Gln Leu

C21H36N6O9 (516.2544)

Phe Phe Phe Gly

C29H32N4O5 (516.2373)

Phe Phe Gly Phe

C29H32N4O5 (516.2373)

Phe Gly Phe Phe

C29H32N4O5 (516.2373)

Gly Phe Phe Phe

C29H32N4O5 (516.2373)

Ile Glu Gln Gln

C21H36N6O9 (516.2544)

Ile Gln Glu Gln

C21H36N6O9 (516.2544)

Ile Gln Gln Glu

C21H36N6O9 (516.2544)

Leu Glu Gln Gln

C21H36N6O9 (516.2544)

Leu Gln Glu Gln

C21H36N6O9 (516.2544)

Leu Gln Gln Glu

C21H36N6O9 (516.2544)

Met Asn Pro Arg

C20H36N8O6S (516.2478)

Met Asn Arg Pro

C20H36N8O6S (516.2478)

Met Pro Asn Arg

C20H36N8O6S (516.2478)

Met Pro Arg Asn

C20H36N8O6S (516.2478)

Met Arg Asn Pro

C20H36N8O6S (516.2478)

Met Arg Pro Asn

C20H36N8O6S (516.2478)

Asn Met Pro Arg

C20H36N8O6S (516.2478)

Asn Met Arg Pro

C20H36N8O6S (516.2478)

Asn Asn Asn Arg

C18H32N10O8 (516.2404)

Asn Asn Arg Asn

C18H32N10O8 (516.2404)

Asn Pro Met Arg

C20H36N8O6S (516.2478)

Asn Pro Arg Met

C20H36N8O6S (516.2478)

Asn Arg Met Pro

C20H36N8O6S (516.2478)

Asn Arg Asn Asn

C18H32N10O8 (516.2404)

Asn Arg Pro Met

C20H36N8O6S (516.2478)

Pro Met Asn Arg

C20H36N8O6S (516.2478)

Pro Met Arg Asn

C20H36N8O6S (516.2478)

Pro Asn Met Arg

C20H36N8O6S (516.2478)

Pro Asn Arg Met

C20H36N8O6S (516.2478)

Pro Arg Met Asn

C20H36N8O6S (516.2478)

Pro Arg Asn Met

C20H36N8O6S (516.2478)

Gln Glu Ile Gln

C21H36N6O9 (516.2544)

Gln Glu Leu Gln

C21H36N6O9 (516.2544)

Gln Glu Gln Ile

C21H36N6O9 (516.2544)

Gln Glu Gln Leu

C21H36N6O9 (516.2544)

Gln Ile Glu Gln

C21H36N6O9 (516.2544)

Gln Ile Gln Glu

C21H36N6O9 (516.2544)

Gln Leu Glu Gln

C21H36N6O9 (516.2544)

Gln Leu Gln Glu

C21H36N6O9 (516.2544)

Gln Gln Glu Ile

C21H36N6O9 (516.2544)

Gln Gln Glu Leu

C21H36N6O9 (516.2544)

Gln Gln Ile Glu

C21H36N6O9 (516.2544)

Gln Gln Leu Glu

C21H36N6O9 (516.2544)

Arg Met Asn Pro

C20H36N8O6S (516.2478)

Arg Met Pro Asn

C20H36N8O6S (516.2478)

Arg Asn Met Pro

C20H36N8O6S (516.2478)

Arg Asn Asn Asn

C18H32N10O8 (516.2404)

Arg Asn Pro Met

C20H36N8O6S (516.2478)

Arg Pro Met Asn

C20H36N8O6S (516.2478)

Arg Pro Asn Met

C20H36N8O6S (516.2478)

PDAKS

C21H36N6O9 (516.2544)

Udenafil

C25H36N6O4S (516.2519)

G - Genito urinary system and sex hormones > G04 - Urologicals > G04B - Urologicals > G04BE - Drugs used in erectile dysfunction D004791 - Enzyme Inhibitors > D010726 - Phosphodiesterase Inhibitors > D058986 - Phosphodiesterase 5 Inhibitors C471 - Enzyme Inhibitor > C744 - Phosphodiesterase Inhibitor > C2127 - cGMP Phosphodiesterase Inhibitor

Austalide A

C28H36O9 (516.2359)

ST 28:7;O9

C28H36O9 (516.2359)

Boc-Ala-Glu-Val-Asp-aldehyde (pseudo acid)

C22H36N4O10 (516.2431)

2-acetamido-3,4,6-tri-o-benzyl-2-deoxy-beta-d-glucopyranosyl azide

C29H32N4O5 (516.2373)

BATES REAGENT MU-OXO-BIS[TRIS(DIMETHYLAMINO)PHOSPHONIUM]BIS(TETRAFLUOROBORATE)

C12H36B2F8N6OP2 (516.2484)

MCOPPB trihydrochloride

C26H43Cl3N4 (516.2553)

MCOPPB trihydrochloride is a nociceptin receptor agonist with pKi of 10.07; weaker activity at other opioid receptors. IC50 value: 10.07 (pKi) Target: nociceptin receptor MCOPPB trihydrochloride is a trihydrochloride form of MCOPPB that is a new nonpeptide nociceptin/orphanin FQ peptide (NOP)-receptor agonist with a pKi of 10.07 ± 0.01 for the human NOP receptor.

alpha-[butylamino]methyl-p-hydroxybenzyl alcohol

C24H40N2O8S (516.2505)

PA(2:0/20:4(6E,8Z,11Z,14Z)-OH(5S))

C25H41O9P (516.2488)

PA(20:4(6E,8Z,11Z,14Z)-OH(5S)/2:0)

C25H41O9P (516.2488)

PA(2:0/20:4(5Z,7E,11Z,14Z)-OH(9))

C25H41O9P (516.2488)

PA(20:4(5Z,7E,11Z,14Z)-OH(9)/2:0)

C25H41O9P (516.2488)

PA(2:0/20:3(5Z,8Z,11Z)-O(14R,15S))

C25H41O9P (516.2488)

PA(20:3(5Z,8Z,11Z)-O(14R,15S)/2:0)

C25H41O9P (516.2488)

PA(2:0/20:3(5Z,8Z,14Z)-O(11S,12R))

C25H41O9P (516.2488)

PA(20:3(5Z,8Z,14Z)-O(11S,12R)/2:0)

C25H41O9P (516.2488)

PA(2:0/20:3(5Z,11Z,14Z)-O(8,9))

C25H41O9P (516.2488)

PA(20:3(5Z,11Z,14Z)-O(8,9)/2:0)

C25H41O9P (516.2488)

PA(2:0/20:3(8Z,11Z,14Z)-O(5,6))

C25H41O9P (516.2488)

PA(20:3(8Z,11Z,14Z)-O(5,6)/2:0)

C25H41O9P (516.2488)

PA(2:0/20:4(5Z,8Z,11Z,14Z)-OH(20))

C25H41O9P (516.2488)

PA(20:4(5Z,8Z,11Z,14Z)-OH(20)/2:0)

C25H41O9P (516.2488)

PA(2:0/20:4(5Z,8Z,11Z,14Z)-OH(19S))

C25H41O9P (516.2488)

PA(20:4(5Z,8Z,11Z,14Z)-OH(19S)/2:0)

C25H41O9P (516.2488)

PA(2:0/20:4(5Z,8Z,11Z,14Z)-OH(18R))

C25H41O9P (516.2488)

PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/2:0)

C25H41O9P (516.2488)

PA(2:0/20:4(5Z,8Z,11Z,14Z)-OH(17))

C25H41O9P (516.2488)

PA(20:4(5Z,8Z,11Z,14Z)-OH(17)/2:0)

C25H41O9P (516.2488)

PA(2:0/20:4(5Z,8Z,11Z,14Z)-OH(16R))

C25H41O9P (516.2488)

PA(20:4(5Z,8Z,11Z,14Z)-OH(16R)/2:0)

C25H41O9P (516.2488)

PA(2:0/20:4(5Z,8Z,11Z,13E)-OH(15S))

C25H41O9P (516.2488)

PA(20:4(5Z,8Z,11Z,13E)-OH(15S)/2:0)

C25H41O9P (516.2488)

PA(2:0/20:4(5Z,8Z,10E,14Z)-OH(12S))

C25H41O9P (516.2488)

PA(20:4(5Z,8Z,10E,14Z)-OH(12S)/2:0)

C25H41O9P (516.2488)

PA(2:0/20:4(5E,8Z,12Z,14Z)-OH(11R))

C25H41O9P (516.2488)

PA(20:4(5E,8Z,12Z,14Z)-OH(11R)/2:0)

C25H41O9P (516.2488)

triptogelin C-1

C28H36O9 (516.2359)

A natural product found particularly in Celastrus orbiculatus and Tripterygium wilfordii regelii.

CID 11756285

C28H36O9 (516.2359)

alpha-((Butylamino)methyl)-p-hydroxybenzyl alcohol sulfate

C24H40N2O8S (516.2505)

C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist

3-cyclopentyl-1-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(3-pyridinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-1-methylurea

C26H36N4O5S (516.2406)

3-cyclopentyl-1-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(3-pyridinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-1-methylurea

C26H36N4O5S (516.2406)

N-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(5-pyrimidinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylcyclohexanecarboxamide

C26H36N4O5S (516.2406)

N-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(5-pyrimidinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylcyclohexanecarboxamide

C26H36N4O5S (516.2406)

N-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(5-pyrimidinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylcyclohexanecarboxamide

C26H36N4O5S (516.2406)

N-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(5-pyrimidinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylcyclohexanecarboxamide

C26H36N4O5S (516.2406)

N-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(5-pyrimidinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylcyclohexanecarboxamide

C26H36N4O5S (516.2406)

N-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(5-pyrimidinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylcyclohexanecarboxamide

C26H36N4O5S (516.2406)

(2S)-2-[(4S,5S)-8-(1-cyclohexenyl)-5-[[(2-fluorophenyl)methyl-methylamino]methyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol

C28H37FN2O4S (516.2458)

3-cyclopentyl-1-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(3-pyridinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-1-methylurea

C26H36N4O5S (516.2406)

3-cyclopentyl-1-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(3-pyridinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-1-methylurea

C26H36N4O5S (516.2406)

3-cyclopentyl-1-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(3-pyridinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-1-methylurea

C26H36N4O5S (516.2406)

3-cyclopentyl-1-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(3-pyridinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-1-methylurea

C26H36N4O5S (516.2406)

3-cyclopentyl-1-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(3-pyridinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-1-methylurea

C26H36N4O5S (516.2406)

3-cyclopentyl-1-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(3-pyridinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-1-methylurea

C26H36N4O5S (516.2406)

N-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(5-pyrimidinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylcyclohexanecarboxamide

C26H36N4O5S (516.2406)

N-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(5-pyrimidinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylcyclohexanecarboxamide

C26H36N4O5S (516.2406)

(2R)-2-[(4S,5S)-8-(1-cyclohexenyl)-5-[[(2-fluorophenyl)methyl-methylamino]methyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol

C28H37FN2O4S (516.2458)

(2R)-2-[(4R,5R)-8-(1-cyclohexenyl)-5-[[(2-fluorophenyl)methyl-methylamino]methyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol

C28H37FN2O4S (516.2458)

(2R)-2-[(4R,5S)-8-(1-cyclohexenyl)-5-[[(2-fluorophenyl)methyl-methylamino]methyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol

C28H37FN2O4S (516.2458)

(2S)-2-[(4S,5R)-8-(1-cyclohexenyl)-5-[[(2-fluorophenyl)methyl-methylamino]methyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol

C28H37FN2O4S (516.2458)

4-[(4-anilinophenyl)-(4-phenyliminocyclohexa-2,5-dien-1-ylidene)methyl]-N-phenylaniline;hydron

C37H30N3+ (516.244)

Ejap-2

C28H36O9 (516.2359)

A natural product found in Celastrus orbiculatus and Euonymus japonicus.

LPA 22:5;O2

C25H41O9P (516.2488)

PA 14:1/8:3;O

C25H41O9P (516.2488)

PA 18:3/4:1;O

C25H41O9P (516.2488)

PA 22:4;O

C25H41O9P (516.2488)

PEth 20:4;O

C25H41O9P (516.2488)

PM 21:4;O

C25H41O9P (516.2488)

ST 22:5;O3;GlcA

C28H36O9 (516.2359)

ST 22:6;O4;Hex

C28H36O9 (516.2359)

ST 25:2;O6;S

C25H40O9S (516.2393)

ST 29:6;O3;S

C29H40O6S (516.2545)

methyl (1s,2r,5r,6s,7s,8s,9r,12r)-5,12-bis(acetyloxy)-7-(benzoyloxy)-2,6,10,10-tetramethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecane-8-carboxylate

C28H36O9 (516.2359)

2,3,11-tris(acetyloxy)-5,5,9-trimethyl-14-methylidene-6-oxotetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadec-7-en-15-yl acetate

C28H36O9 (516.2359)

5,8,12-tris(acetyloxy)-2,6,10,10-tetramethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate

C28H36O9 (516.2359)

4,5,8-tris(acetyloxy)-2,6,10,10-tetramethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate

C28H36O9 (516.2359)

(1s,2r,5s,6s,8r,10s,11s,12r,14r,15r,16s,19s,21r)-6-(furan-3-yl)-12,16,19-trihydroxy-5,11,15-trimethyl-3-oxo-9,17-dioxahexacyclo[13.3.3.0¹,¹⁴.0²,¹¹.0⁵,¹⁰.0⁸,¹⁰]henicosan-21-yl acetate

C28H36O9 (516.2359)

(1s,2r,4s,5r,6r,7s,9r)-4,5-bis(acetyloxy)-6-[(acetyloxy)methyl]-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate

C28H36O9 (516.2359)

4-[11a-(acetyloxy)-3a,6,6,9a-tetramethyl-3,4,7,10-tetraoxo-1h,2h,5h,5ah,8h,9h,11h-cyclopenta[a]phenanthren-1-yl]-4-hydroxypentanoic acid

C28H36O9 (516.2359)

(1s,2s,5s,6s,7s,9r,12r)-12-(acetyloxy)-2-hydroxy-5-[(2-hydroxyacetyl)oxy]-2,6,10,10-tetramethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl (2e)-3-phenylprop-2-enoate

C28H36O9 (516.2359)

9,14-dihydroxy-3,4,5,15,16-pentamethoxy-9,10-dimethyltricyclo[10.4.0.0²,⁷]hexadeca-1(12),2,4,6,13,15-hexaen-8-yl 2-methylbut-2-enoate

C28H36O9 (516.2359)

(1r,2s,4s,5s,6r,7s,8r,9r)-4,5,8-tris(acetyloxy)-2,6,10,10-tetramethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate

C28H36O9 (516.2359)

(8r,9r,10s)-9,14-dihydroxy-3,4,5,15,16-pentamethoxy-9,10-dimethyltricyclo[10.4.0.0²,⁷]hexadeca-1(12),2,4,6,13,15-hexaen-8-yl (2e)-2-methylbut-2-enoate

C28H36O9 (516.2359)

(1s,2s,4r,5r,6r,7s,9r,12r)-7,12-bis(acetyloxy)-2,4-dihydroxy-2,6,10,10-tetramethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-5-yl (2e)-3-phenylprop-2-enoate

C28H36O9 (516.2359)

(8s,9r,10r)-9,14-dihydroxy-3,4,5,15,16-pentamethoxy-9,10-dimethyltricyclo[10.4.0.0²,⁷]hexadeca-1(12),2,4,6,13,15-hexaen-8-yl (2z)-2-methylbut-2-enoate

C28H36O9 (516.2359)

2-[(1s,2r,5s,8s,10r,11r,15r)-8-hydroxy-11-methyl-15-[(2s)-1-[(2z)-4-methyl-5-oxofuran-2-ylidene]propan-2-yl]-6,13-dioxo-14,16-dioxatetracyclo[8.6.0.0²,⁸.0¹¹,¹⁵]hexadecan-5-yl]propan-2-yl acetate

C28H36O9 (516.2359)

5,8-bis(acetyloxy)-6-[(acetyloxy)methyl]-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate

C28H36O9 (516.2359)

7,12-bis(acetyloxy)-2,4-dihydroxy-2,6,10,10-tetramethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-5-yl 3-phenylprop-2-enoate

C28H36O9 (516.2359)

(1r,2r,6s,7r,9s)-4,13-bis[(4e)-hex-4-enoyl]-3,6,7,10,12-pentahydroxy-2,6,9,11-tetramethyl-8-oxatricyclo[7.4.0.0²,⁷]trideca-3,10,12-trien-5-one

C28H36O9 (516.2359)

5,7-dihydroxy-2-(4-hydroxy-3,5-dimethoxyphenyl)-6-[(2e)-6-hydroxy-7-methoxy-3,7-dimethyloct-2-en-1-yl]-2,3-dihydro-1-benzopyran-4-one

C28H36O9 (516.2359)

(8s,9s,10s)-9-hydroxy-3,4,5,14,15,16-hexamethoxy-9,10-dimethyltricyclo[10.4.0.0²,⁷]hexadeca-1(12),2,4,6,13,15-hexaen-8-yl but-2-enoate

C28H36O9 (516.2359)

methyl (2s,4as,4bs,5s,6r,6as,10as,10bs,12as)-6-(acetyloxy)-5-hydroxy-2,4b,7,7,10a,12a-hexamethyl-12-methylidene-1,4,8-trioxo-4ah,5h,6h,6ah,10bh,11h-phenanthro[1,2-c]pyran-2-carboxylate

C28H36O9 (516.2359)

(1s,2r,5s,6s,7s,8r,9s)-5,8-bis(acetyloxy)-6-[(acetyloxy)methyl]-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate

C28H36O9 (516.2359)

13-(1,6-dihydroxyhexa-2,4-dien-1-ylidene)-4-(hex-4-enoyl)-6,7,12-trihydroxy-2,6,9,11-tetramethyl-8-oxatricyclo[7.4.0.0²,⁷]tridec-11-ene-3,10-dione

C28H36O9 (516.2359)

(1s,2s,5s,6s,8r,10r,11s,12r,14r,15r,16r,19s,21r)-6-(furan-3-yl)-12,16,19-trihydroxy-5,11,15-trimethyl-3-oxo-9,17-dioxahexacyclo[13.3.3.0¹,¹⁴.0²,¹¹.0⁵,¹⁰.0⁸,¹⁰]henicosan-21-yl acetate

C28H36O9 (516.2359)

(8s,9s,10s)-9-hydroxy-3,4,5,14,15,16-hexamethoxy-9,10-dimethyltricyclo[10.4.0.0²,⁷]hexadeca-1(12),2,4,6,13,15-hexaen-8-yl (2z)-but-2-enoate

C28H36O9 (516.2359)

13,20-dimethoxy-4,7,17,22,22-pentamethyl-11-oxo-5,10,21,23-tetraoxahexacyclo[18.2.1.0¹,¹⁷.0⁴,¹⁶.0⁶,¹⁴.0⁸,¹²]tricosa-6,8(12),13-trien-2-yl acetate

C28H36O9 (516.2359)

4,5,12-tris(acetyloxy)-2,6,10,10-tetramethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate

C28H36O9 (516.2359)

4-[(1r,3as,5ar,9as,11as)-11a-(acetyloxy)-3a,6,6,9a-tetramethyl-3,4,7,10-tetraoxo-1h,2h,5h,5ah,8h,9h,11h-cyclopenta[a]phenanthren-1-yl]-4-hydroxypentanoic acid

C28H36O9 (516.2359)

methyl 6-(acetyloxy)-5-hydroxy-2,4b,7,7,10a,12a-hexamethyl-12-methylidene-1,4,8-trioxo-4ah,5h,6h,6ah,10bh,11h-phenanthro[1,2-c]pyran-2-carboxylate

C28H36O9 (516.2359)

(1s,3r,4s,7r,8r,11r,12r,15s,16s,18r,20s,25r,26s,28s)-1,7,12-trihydroxy-7,8,25,28-tetramethyl-2,5,9,19-tetraoxaoctacyclo[13.12.1.0³,¹¹.0⁴,⁸.0¹²,²⁸.0¹⁶,²⁶.0¹⁸,²⁰.0²⁰,²⁵]octacos-22-ene-6,24-dione

C28H36O9 (516.2359)

12-(acetyloxy)-2-hydroxy-5-[(2-hydroxyacetyl)oxy]-2,6,10,10-tetramethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl 3-phenylprop-2-enoate

C28H36O9 (516.2359)

methyl 5,12-bis(acetyloxy)-7-(benzoyloxy)-2,6,10,10-tetramethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecane-8-carboxylate

C28H36O9 (516.2359)

(8s,9r,10s)-9,14-dihydroxy-3,4,5,15,16-pentamethoxy-9,10-dimethyltricyclo[10.4.0.0²,⁷]hexadeca-1(12),2,4,6,13,15-hexaen-8-yl (2e)-2-methylbut-2-enoate

C28H36O9 (516.2359)

(1r,2r,6s,7r,9s)-13-(1,6-dihydroxyhexa-2,4-dien-1-ylidene)-4-(hex-4-enoyl)-6,7,12-trihydroxy-2,6,9,11-tetramethyl-8-oxatricyclo[7.4.0.0²,⁷]tridec-11-ene-3,10-dione

C28H36O9 (516.2359)

4,5-bis(acetyloxy)-6-[(acetyloxy)methyl]-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate

C28H36O9 (516.2359)

1,7,12-trihydroxy-7,8,25,28-tetramethyl-2,5,9,19-tetraoxaoctacyclo[13.12.1.0³,¹¹.0⁴,⁸.0¹²,²⁸.0¹⁶,²⁶.0¹⁸,²⁰.0²⁰,²⁵]octacos-22-ene-6,24-dione

C28H36O9 (516.2359)

6-(furan-3-yl)-12,16,19-trihydroxy-5,11,15-trimethyl-3-oxo-9,17-dioxahexacyclo[13.3.3.0¹,¹⁴.0²,¹¹.0⁵,¹⁰.0⁸,¹⁰]henicosan-21-yl acetate

C28H36O9 (516.2359)

methyl 15-(acetyloxy)-7-hydroxy-4,5,7,10,14,14-hexamethyl-6,8,18-trioxo-19-oxapentacyclo[10.5.2.0¹,¹³.0²,¹⁰.0⁵,⁹]nonadec-3-ene-9-carboxylate

C28H36O9 (516.2359)

16-hydroxy-4,9,11,17,19,19-hexamethyl-2,6,18,25,26-pentaoxaoctacyclo[12.10.1.1¹,⁸.1¹⁷,²².0³,⁷.0¹⁴,²³.0¹⁶,²⁰.0¹¹,²⁷]heptacosane-5,10,24-trione

C28H36O9 (516.2359)

(1s,2r,5s,6s,7r,8r,9r,12r)-5,8,12-tris(acetyloxy)-2,6,10,10-tetramethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate

C28H36O9 (516.2359)

methyl (2e)-4-({2-[(1e,3e,5e)-6-[(2r,3r,3ar,4r,5r,6as)-5-ethyl-3,4-dihydroxy-3a,4-dimethyl-tetrahydrofuro[2,3-b]furan-2-yl]hexa-1,3,5-trien-1-yl]-3-methyl-6-oxopyran-4-yl}oxy)-2-methylbut-2-enoate

C28H36O9 (516.2359)

2-[(1s,2r,5s,8s,10r,11r,15r)-8-hydroxy-11-methyl-15-[(2r)-1-[(2z)-4-methyl-5-oxofuran-2-ylidene]propan-2-yl]-6,13-dioxo-14,16-dioxatetracyclo[8.6.0.0²,⁸.0¹¹,¹⁵]hexadecan-5-yl]propan-2-yl acetate

C28H36O9 (516.2359)

(1s,2s,5s,6s,7s,9r,12r)-5-(acetyloxy)-6-[(acetyloxy)methyl]-2,12-dihydroxy-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl (2e)-3-phenylprop-2-enoate

C28H36O9 (516.2359)

2-{8-hydroxy-11-methyl-15-[1-(4-methyl-5-oxofuran-2-ylidene)propan-2-yl]-6,13-dioxo-14,16-dioxatetracyclo[8.6.0.0²,⁸.0¹¹,¹⁵]hexadecan-5-yl}propan-2-yl acetate

C28H36O9 (516.2359)

methyl (1r,5r,7s,9r,10s,12s,15s)-15-(acetyloxy)-7-hydroxy-4,5,7,10,14,14-hexamethyl-6,8,18-trioxo-19-oxapentacyclo[10.5.2.0¹,¹³.0²,¹⁰.0⁵,⁹]nonadec-3-ene-9-carboxylate

C28H36O9 (516.2359)

(1r,2r,4s,16r,17r,20s)-13,20-dimethoxy-4,7,17,22,22-pentamethyl-11-oxo-5,10,21,23-tetraoxahexacyclo[18.2.1.0¹,¹⁷.0⁴,¹⁶.0⁶,¹⁴.0⁸,¹²]tricosa-6,8(12),13-trien-2-yl acetate

C28H36O9 (516.2359)

(1s,2r,3r,4s,9s,10s,11s,13r,15r)-2,3,11-tris(acetyloxy)-5,5,9-trimethyl-14-methylidene-6-oxotetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadec-7-en-15-yl acetate

C28H36O9 (516.2359)

(1s,2s,5s,6s,7s,9r,12s)-5,12-bis(acetyloxy)-2-[(acetyloxy)methyl]-6,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate

C28H36O9 (516.2359)

(1s,3r,7r,10s,12r,13r,17r,18s,19s,21s,22s)-1,12,22-trihydroxy-9,9,18-trimethyl-19-[(2r)-4-methyl-5-oxo-2h-furan-2-yl]-4,8,20-trioxahexacyclo[11.10.0.0³,⁷.0³,¹⁰.0¹⁴,²¹.0¹⁷,²¹]tricos-14-en-5-one

C28H36O9 (516.2359)

methyl 4-{[2-(6-{5-ethyl-3,4-dihydroxy-3a,4-dimethyl-tetrahydrofuro[2,3-b]furan-2-yl}hexa-1,3,5-trien-1-yl)-3-methyl-6-oxopyran-4-yl]oxy}-2-methylbut-2-enoate

C28H36O9 (516.2359)

2',8',10',12'-tetrahydroxy-3,4,9',15',22'-pentamethyl-18',19'-dioxaspiro[furan-2,11'-hexacyclo[15.2.2.1⁵,⁸.0¹,¹⁵.0⁴,¹⁴.0¹²,²²]docosan]-20'-ene-5,16'-dione

C28H36O9 (516.2359)

(1s,2r,5s,6s,7s,8s,9s)-5,8-bis(acetyloxy)-6-[(acetyloxy)methyl]-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate

C28H36O9 (516.2359)

5,12-bis(acetyloxy)-6-[(acetyloxy)methyl]-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate

C28H36O9 (516.2359)

5,12-bis(acetyloxy)-2-[(acetyloxy)methyl]-6,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate

C28H36O9 (516.2359)

4,13-bis(hex-4-enoyl)-3,6,7,10,12-pentahydroxy-2,6,9,11-tetramethyl-8-oxatricyclo[7.4.0.0²,⁷]trideca-3,10,12-trien-5-one

C28H36O9 (516.2359)

12-hydroxy-8,21,21-trimethyl-5,19-bis(3-methylbut-2-en-1-yl)-3,7,20-trioxahexacyclo[15.4.1.0²,¹⁵.0²,¹⁹.0⁴,¹³.0⁶,¹¹]docosa-4(13),5,9,11,15-pentaene-14,18-dione

C32H36O6 (516.2512)

(1s,2s,8s,17s,19r)-12-hydroxy-8,21,21-trimethyl-5,19-bis(3-methylbut-2-en-1-yl)-3,7,20-trioxahexacyclo[15.4.1.0²,¹⁵.0²,¹⁹.0⁴,¹³.0⁶,¹¹]docosa-4(13),5,9,11,15-pentaene-14,18-dione

C32H36O6 (516.2512)

(1s,2s,5s,6r,9r,10s,11r,13r,14r,15s,18s,20r)-6-(furan-3-yl)-11,15,18-trihydroxy-5,10,14-trimethyl-3,8-dioxo-16-oxapentacyclo[12.3.3.0¹,¹³.0²,¹⁰.0⁵,⁹]icosan-20-yl acetate

C28H36O9 (516.2359)

(1s,2r,5s,6s,7s,8s,9r,12r)-5,8,12-tris(acetyloxy)-2,6,10,10-tetramethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate

C28H36O9 (516.2359)

(1s,3r,4s,7r,8s,9s,11s,14s,16r,17r,20r,22s,23r,27s)-16-hydroxy-4,9,11,17,19,19-hexamethyl-2,6,18,25,26-pentaoxaoctacyclo[12.10.1.1¹,⁸.1¹⁷,²².0³,⁷.0¹⁴,²³.0¹⁶,²⁰.0¹¹,²⁷]heptacosane-5,10,24-trione

C28H36O9 (516.2359)

(1s,2r,5s,6s,8r,10r,11s,12r,14r,15r,16r,19s,21r)-6-(furan-3-yl)-12,16,19-trihydroxy-5,11,15-trimethyl-3-oxo-9,17-dioxahexacyclo[13.3.3.0¹,¹⁴.0²,¹¹.0⁵,¹⁰.0⁸,¹⁰]henicosan-21-yl acetate

C28H36O9 (516.2359)

(8s,9s,10s)-9,14-dihydroxy-3,4,5,15,16-pentamethoxy-9,10-dimethyltricyclo[10.4.0.0²,⁷]hexadeca-1(12),2,4,6,13,15-hexaen-8-yl (2e)-2-methylbut-2-enoate

C28H36O9 (516.2359)